Could a parasite drug boost cancer immunotherapy? new trial investigates

NCT ID NCT05318469

First seen Jun 27, 2026 · Last updated Aug 06, 2026 · Updated 2 times

Summary

This study tests whether adding ivermectin (a drug used for parasitic infections) to standard immunotherapy drugs (balstilimab or pembrolizumab) can shrink tumors in people with metastatic triple-negative breast cancer. The trial has two phases: first, finding the safest dose of ivermectin, and second, checking how well the combination works. About 34 participants will be enrolled.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
ivermectin combined with balstilimab or pembrolizumab
What this could lead to
If it works, this could offer a new treatment option for people with metastatic triple-negative breast cancer, potentially shrinking tumors and extending life.
What could go wrong
This is an early-phase trial with only 34 participants, so results are uncertain. Ivermectin is not a standard cancer drug, and combining it with immunotherapy may cause unexpected side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANATOMIC STAGE IV BREAST CANCER AJCC V8 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Cedars-Sinai Medical Center

    RECRUITING

    Los Angeles, California, 90048, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.